198 related articles for article (PubMed ID: 21683222)
1. Brain lipid-binding protein: a marker of differentiation in neuroblastic tumors.
Retrosi G; Sebire NJ; Bishay M; Kiely EM; Anderson J; De Coppi P; Resca E; Rampling D; Bier N; Mills K; Eaton S; Pierro A
J Pediatr Surg; 2011 Jun; 46(6):1197-200. PubMed ID: 21683222
[TBL] [Abstract][Full Text] [Related]
2. Role of diffusion-weighted imaging in distinguishing thoracoabdominal neuroblastic tumours of various histological types and differentiation grades.
Wen Y; Peng Y; Duan XM; Zhang N
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):718-724. PubMed ID: 28508462
[TBL] [Abstract][Full Text] [Related]
3. Cytopathological spectrum of peripheral neuroblastic tumours in fine needle aspiration cytology and categorisation as per International Neuroblastoma Pathology Classification.
Koshy A; Jain R; Srinivasan R; Bhatia P; Kakkar N; Rajwanshi A; Gupta N; Dey P; Trehan A; Bansal D
Cytopathology; 2019 Nov; 30(6):634-643. PubMed ID: 31231909
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of benign neuroblastic tumors: Is surgery always necessary?
Whitlock RS; Mehl SC; Larson SK; Foster JH; Hicks J; Nuchtern JG; Sher AC; Vasudevan SA; Naik-Mathuria B
J Pediatr Surg; 2022 Aug; 57(8):1538-1543. PubMed ID: 34281709
[TBL] [Abstract][Full Text] [Related]
5. Extra-adrenal peripheral neuroblastic tumors: A clinicopathological study of 18 cases.
Shankaralingappa S; Patra S; Gami A; Trivedi P; Chalaliya AK
Indian J Pathol Microbiol; 2023; 66(2):278-285. PubMed ID: 37077068
[TBL] [Abstract][Full Text] [Related]
6. The International Neuroblastoma Pathology Classification (the Shimada system).
Shimada H; Ambros IM; Dehner LP; Hata J; Joshi VV; Roald B; Stram DO; Gerbing RB; Lukens JN; Matthay KK; Castleberry RP
Cancer; 1999 Jul; 86(2):364-72. PubMed ID: 10421273
[TBL] [Abstract][Full Text] [Related]
7. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.
Shimada H; Ambros IM; Dehner LP; Hata J; Joshi VV; Roald B
Cancer; 1999 Jul; 86(2):349-63. PubMed ID: 10421272
[TBL] [Abstract][Full Text] [Related]
8. An ultrastructural and immunohistochemical evaluation of cytodifferentiation in neuroblastic tumors.
Hachitanda Y; Tsuneyoshi M; Enjoji M
Mod Pathol; 1989 Jan; 2(1):13-9. PubMed ID: 2922387
[TBL] [Abstract][Full Text] [Related]
9. Utility of Phox2b immunohistochemical stain in neural crest tumours and non-neural crest tumours in paediatric patients.
Warren M; Matsuno R; Tran H; Shimada H
Histopathology; 2018 Mar; 72(4):685-696. PubMed ID: 28986989
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathologic features of peripheral neuroblastic tumors].
Yang BF; Fu LB; He LJ
Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):305-10. PubMed ID: 24004586
[TBL] [Abstract][Full Text] [Related]
11. ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.
Wilzén A; Krona C; Sveinbjörnsson B; Kristiansson E; Dalevi D; Øra I; De Preter K; Stallings RL; Maris J; Versteeg R; Nilsson S; Kogner P; Abel F
Mol Cancer; 2013 Jul; 12(1):70. PubMed ID: 23835063
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 in pediatric neuroblastic tumors: A microarray analysis.
Fagone P; Nicoletti F; Vecchio GM; Parenti R; Magro G
Acta Histochem; 2015 Oct; 117(8):820-3. PubMed ID: 26510683
[TBL] [Abstract][Full Text] [Related]
13. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Shimada H; Umehara S; Monobe Y; Hachitanda Y; Nakagawa A; Goto S; Gerbing RB; Stram DO; Lukens JN; Matthay KK
Cancer; 2001 Nov; 92(9):2451-61. PubMed ID: 11745303
[TBL] [Abstract][Full Text] [Related]
14. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors.
Maitra A; Yashima K; Rathi A; Timmons CF; Rogers BB; Shay JW; Gazdar AF
Cancer; 1999 Feb; 85(3):741-9. PubMed ID: 10091748
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.
Okamatsu C; London WB; Naranjo A; Hogarty MD; Gastier-Foster JM; Look AT; LaQuaglia M; Maris JM; Cohn SL; Matthay KK; Seeger RC; Saji T; Shimada H
Pediatr Blood Cancer; 2009 Oct; 53(4):563-9. PubMed ID: 19530234
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Value of Diffusion-Weighted MRI for Tumor Characterization, Differentiation and Monitoring in Pediatric Patients with Neuroblastic Tumors.
Neubauer H; Li M; Müller VR; Pabst T; Beer M
Rofo; 2017 Jul; 189(7):640-650. PubMed ID: 28511265
[No Abstract] [Full Text] [Related]
17. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.
Veschi V; Petroni M; Bartolazzi A; Altavista P; Dominici C; Capalbo C; Boldrini R; Castellano A; McDowell HP; Pizer B; Frati L; Screpanti I; Gulino A; Giannini G
Cell Death Dis; 2014 Mar; 5(3):e1100. PubMed ID: 24603328
[TBL] [Abstract][Full Text] [Related]
18. [Peripheral neuroblastic tumors: anatomo pathological classification].
Peuchmaur M
Ann Pathol; 2004 Dec; 24(6):556-67. PubMed ID: 15785402
[TBL] [Abstract][Full Text] [Related]
19. Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed.
Decarolis B; Simon T; Krug B; Leuschner I; Vokuhl C; Kaatsch P; von Schweinitz D; Klingebiel T; Mueller I; Schweigerer L; Berthold F; Hero B
BMC Cancer; 2016 Jul; 16():542. PubMed ID: 27465021
[TBL] [Abstract][Full Text] [Related]
20. Exome sequencing identifies predisposing and fusion gene in ganglioneuroma, ganglioneuroblastoma and neuroblastoma.
Wu W; Xu WJ; Liu JB; Sun J; Huang YM; Lv ZB
Math Biosci Eng; 2019 Aug; 16(6):7217-7229. PubMed ID: 31698611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
